Lundbeck & Otsuka Report Positive Phase II Data For The Combination Treatment Of Brexpiprazole & Sertraline For The Treatment Of PTSD

Global pharmaceutical companies Otsuka Pharmaceutical (Otsuka) and Lundbeck recently reported positive data for a phase II trial designed to assess the efficacy, safety, and tolerability of brexpiprazole and sertraline in adults with post-traumatic stress disorder (PTSD). Brexpiprazole is used to treat the symptoms of schizophrenia, and can also be used with an antidepressant to help treat depression. Sertraline is a drug intended for the treatment of depression, obsessive-compulsive disorder, PTSD, and other mental disorders.

The phase II trial found that both drugs—whether taken individually or in combination with each other—demonstrated improvement in PTSD symptoms compared to . . .